Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
eczema
Biotech
Sanofi pays Regeneron $1B for 4 early-stage assets to ignite R&D
The deal, which features $7 billion in milestones, tees the longstanding partners up to try to replicate Dupixent’s success.
Nick Paul Taylor
Oct 1, 2026 4:24am
Regeneron backs $75M series A for antibody upstart Infinimmune
Aug 11, 2026 8:00am
Sanofi won't seek approval for eczema drug from Kymab buyout
Jul 24, 2026 5:13am
Attovia files for IPO to take on Sanofi and Regeneron’s Dupixent
Jul 15, 2026 4:09am
AbbVie inks $10.9B Apogee buyout to bag eczema prospect
Jun 22, 2026 7:59am
Apogee bags $1.3B royalty funding deal to advance eczema hopeful
May 27, 2026 8:57am
